article thumbnail

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

The Pharma Data

launch in 2027 — a significant milestone in its mission to bring forward a one-time, potentially curative treatment for hereditary angioedema. Furthermore, Intellia plans to submit a biologics license application (BLA) in 2026 in support of a potential U.S.

article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Drive: Drug Pricing

Data from that trial is expected in 2027. “I His research, writing offer clues. His research, writing offer clues. Vor is paying RemeGene $45 million upfront along with $80 million in warrants to purchase common stock in exchange for the drug, called telitacicept. Europe and South America, according to the companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

BioPharma Drive: Drug Pricing

In a statement Monday , Sarepta said it plans to cut approximately 36% of its staff and pause research on several drug programs. Elevidys is the product of many years of research into the deadly neuromuscular condition and, in 2023 , became the first and currently only gene therapy for the disease approved in the U.S.

article thumbnail

Fourth IHR Emergency Meeting on 2024 Mpox Surge – Temporary Recommendations

The Pharma Data

The latest guidance complements existing standing recommendations and aligns with WHO’s Strategic Framework for Enhancing Prevention and Control of Mpox: 2024–2027. Embedding mpox activities within existing programs addressing HIV, malaria, tuberculosis, STIs, and non-communicable diseases (NCDs) to optimize health system outcomes.

article thumbnail

Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules

BioPharma Drive: Drug Pricing

The company now expects to end 2027 with $700 million in cash, an increase of $400 million from previous guidance. Biocryst said it will use the proceeds to pay off about $249 million in term debt owed to Pharmakon Advisors , which it said will save $70 million in interest. By Delilah Alvarado • May 13, 2025 Keep up with the story.

article thumbnail

CroíValve Secures Horizon Europe EIC Accelerator Funding

The Pharma Data

The EIC Accelerator Programme is part of the broader Horizon Europe 2021–2027 Research and Innovation framework, which provides non-dilutive and equity funding to breakthrough, high-risk innovations with global market potential.

article thumbnail

7 Ideas to Implement & Maintain a Research Data Management Platform

thought leadership

billion USD by 2027, with the goal of improving the generation, collation, storage, and utilization of data 1. Investments in digital transformations are expected to grow from $594.5 billion USD in 2022 to $1.548.9 This drive to better manage and protect data is not a luxury.